Abstract: A backlight module includes a light guide panel, and first and second light sources. The light guide panel has a light-emitting surface and a bottom surface opposite to each other. Two adjacent sides of the bottom surface are respectively connected to a first light-incident surface, and a second light-incident surface. The first and second light sources are disposed adjacent to the first and second light-incident surfaces, respectively. Light-guiding patterns are arranged on the bottom surface or the light-emitting surface. Any adjacent two of the light-guiding patterns have a first pitch in a first direction and a second pitch in a second direction, respectively. The first pitch is decreased gradually from a position near the first light-incident surface toward a position far from the first light-incident surface. The second pitch is decreased gradually from a position near the second light-incident surface toward a position far from the second light-incident surface.

Abstract: A backlight module includes a light guide panel, and first and second light sources. The light guide panel has a light-emitting surface and a bottom surface opposite to each other. Two adjacent sides of the bottom surface are respectively connected to a first light-incident surface, and a second light-incident surface. The first and second light sources are disposed adjacent to the first and second light-incident surfaces, respectively. Light-guiding patterns are arranged on the bottom surface or the light-emitting surface. Any adjacent two of the light-guiding patterns have a first pitch in a first direction and a second pitch in a second direction, respectively. The first pitch is decreased gradually from a position near the first light-incident surface toward a position far from the first light-incident surface. The second pitch is decreased gradually from a position near the second light-incident surface toward a position far from the second light-incident surface.

Abstract: A highly purified and specific glycosaminoglycan degrading enzyme, chondroitinase AC, and to a lesser extent, chondroitinase B, can be used in the treatment of metastatic cancers and in other disorders characterized by angiogenesis. The enzymatic removal of chondroitin sulfates A and C, and to a lesser extent, chondroitin sulfate B, from cell surfaces directly decreases the ability of tumor cells to invade blood vessels and thus prevents the formation of metastatic, or secondary tumors; inhibits tumor cell growth; and decreases angiogenesis by inhibiting both endothelial cell proliferation and capillary formation. Decreasing the formation of new blood vessels into the tumor in turn decreases the potential for tumor growth, and further decreases the ability of tumor cells to invade the bloodstream. These effects are opposite to the prometastatic effects of tumor-secreted heparanase.

Abstract: A highly purified and specific glycosaminoglycan degrading enzyme, chondroitinase AC, and to a lesser extent, chondroitinase B, can be used in the treatment of metastatic cancers and in other disorders characterized by angiogenesis. The enzymatic removal of chondroitin sulfates A and C, and to a lesser extent, chondroitin sulfate B, from cell surfaces directly decreases the ability of tumor cells to invade blood vessels and thus prevents the formation of metastatic, or secondary tumors; inhibits tumor cell growth; and decreases angiogenesis by inhibiting both endothelial cell proliferation and capillary formation. Decreasing the formation of new blood vessels into the tumor in turn decreases the potential for tumor growth, and further decreases the ability of tumor cells to invade the bloodstream. These effects are opposite to the pro-metastatic effects of tumor-secreted heparanase.